THESEUS PHARMACEUTICALS INC's ticker is and the CUSIP is 88369M101. A total of 70 filers reported holding THESEUS PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $8,578,107 | +41.8% | 2,118,051 | -5.8% | 0.46% | +14.2% |
| Q3 2023 | $6,047,642 | -71.2% | 2,248,194 | 0.0% | 0.40% | -67.9% |
| Q2 2023 | $20,975,650 | +5.1% | 2,248,194 | 0.0% | 1.25% | -13.3% |
| Q1 2023 | $19,963,963 | +186.7% | 2,248,194 | +60.8% | 1.44% | +233.7% |
| Q4 2022 | $6,963,006 | – | 1,398,194 | – | 0.43% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 3,585,346 | $33,451,278 | 24.43% |
| Lynx1 Capital Management LP | 757,009 | $7,062,894 | 4.63% |
| Omega Fund Management, LLC | 711,479 | $6,638,099 | 3.72% |
| Orbimed Advisors | 17,233,668 | $160,790,122 | 2.91% |
| Nextech Invest Ltd. | 611,310 | $5,703,522 | 1.94% |
| Paradigm Biocapital Advisors LP | 1,950,327 | $18,196,551 | 1.41% |
| Opaleye Management Inc. | 597,500 | $5,574,675 | 1.33% |
| Frazier Life Sciences Management, L.P. | 2,248,194 | $20,975,650 | 1.25% |
| VR Adviser, LLC | 770,000 | $7,184,100 | 1.15% |
| Affinity Asset Advisors, LLC | 240,244 | $2,241,477 | 0.78% |